Role of Ck-19, Hbme-1 and Galectin-3 in Prediction of Prognosis of Papillary Thyroid Carcinoma - An Experience from a Tertiary Care Centre
Keywords:
papillary thyroid carcinoma (PTC), total tumor diameter (TTD), cytokeratin 19, prognostic markers.
Abstract
Abstract not found
Downloads
How to Cite
References
Dina El Demellawy, Ahmed Nasr, Salem Alowami (2008) Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid. 3(1), 5.
Michel Nasr, Sanjay Mukhopadhyay, Shengle Zhang, Anna-Luise Katzenstein (2006) Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: utility of HBME1 combined with CK19 immunostaining. 19(12), 1631-1637.
David Finley, Nimmi Arora, Baixin Zhu, Lisa Gallagher, Thomas Fahey (2004) Molecular Profiling Distinguishes Papillary Carcinoma from Benign Thyroid Nodules. 89(7), 3214-3223.
A Balta, A Filiz, Kurt Sucullu, I Yucel, E Akin, M (2012) Prognostic value of oncoprotein expressions in thyroid papillary carcinoma. 29(2), 734-741.
V Livolsi (1990) Surgical pathology of the thyroid. 5.
J Rosai, M Carcangiu, R Delellis (1992) Unknown Title. 5.
De Matos, P S Ferreira, A Oliveira Facuri, F Assumpcao, L, Metze Ward, L S (2005) Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. 47, 391-401.
Sven Saussez, Daniel Glinoer, Gilbert Chantrain, Francois Pattou, Bruno Carnaille, Sabine André, Hans-Joachim Gabius, Guy Laurent (2008) Serum Galectin-1 and Galectin-3 Levels in Benign and Malignant Nodular Thyroid Disease. 18(7), 705-712.
R Delellis, E Williams (2004) The WHO classification of tumours of endocrine organs. 50-133.
E D Rossi, M Raffaelli, A Mule', A Miraglia, C P Lombardi, F Vecchio, G Fadda (2006) Simultaneous immunohistochemical expression of HBME‐1 and galectin‐3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid. 48(7), 795-800.
Zubair Baloch, Susan Abraham, Shelly Roberts, Virginia Livolsi (1999) Differential expression of cytokeratins in follicular variant of papillary carcinoma: An immunohistochemical study and its diagnostic utility. 30(10), 1166-1171.
T Yoshii, H Inohara, Y Takenaka, Y Honjo, S Akahani, T Nomura, A Raz, T Kubo (2001) Galectin-3 maintains the transformed phenotype of thyroid papillary carcinoma cells. 18, 787-792.
Z Liu, X Xun, Y Wang, L Mei, L He, W Zeng, C Wang, H Tao (2014) MRI and ultrasonography detection of cervical lymph node metastases in differentiated thyroid carcinoma before reoperation. 6, 147-154.
Sophie Leboulleux, Lars Bastholt, Thomas Krause, Christelle De La Fouchardiere, Jan Tennvall, Ahmad Awada, José Gómez, Françoise Bonichon, Laurence Leenhardt, Christine Soufflet, Muriel Licour, Martin Schlumberger (2012) Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. 13(9), 897-905.
Tijana Isic Dencic, Dubravka Cvejic, Ivan Paunovic, Svetislav Tatic, Marija Havelka, Svetlana Savin (2013) Cytokeratin19 expression discriminates papillary thyroid carcinoma from other thyroid lesions and predicts its aggressive behavior. 30(1), 362.
Gomez Saez, J (2010) Diagnostic usefulness of tumor markers in the thyroid cytological samples extracted by fine-needle aspiration biopsy. 10, 47-56.
M L Prasad, N Pellegata, Y Huang (2005) Galectin-3, fibro -nectin-1, CITED-1, HBME-1 and cytokeratin-19 immunohistochemistry. is useful for the differential diagnosis of thyroid tumors. 18, 48-57.
Tiziana Pisani, Maria Giovagnoli, Francesco Intrieri, Aldo Vecchione (2004) Tall Cell Variant of Papillary Carcinoma Coexisting with Chronic Lymphocytic Thyroiditis. 43(3), 435-438.
Published
2019-08-17
Issue
Section
License
Copyright (c) 2019 Authors and Global Journals Private Limited
This work is licensed under a Creative Commons Attribution 4.0 International License.